The RA-MAP Consortium: a working model for academia-industry collaboration

Research output: Contribution to journalReview articlepeer-review


  • Andrew P Cope
  • Michael R Barnes
  • Alexandra Belson
  • Michael Binks
  • Sarah Brockbank
  • Francisco Bonachela-Capdevila
  • Claudio Carini
  • Benjamin Fisher
  • Carl S Goodyear
  • Paul Emery
  • Michael R Ehrenstein
  • Neil Gozzard
  • Ray Harris
  • Sally Hollis
  • Sarah Keidel
  • Marc Levesque
  • Catharina Lindholm
  • Michael F McDermott
  • Iain B McInnes
  • Christopher M Mela
  • Gerry Parker
  • Simon Read
  • Ayako Wakatsuki Pedersen
  • Frederique Ponchel
  • Duncan Porter
  • Ravi Rao
  • Anthony Rowe
  • Peter Schulz-Knappe
  • Matthew A Sleeman
  • Deborah Symmons
  • Peter C Taylor
  • Brian Tom
  • Wayne Tsuji
  • Denny Verbeeck
  • John D Isaacs
  • RA-MAP Consortium
  • Stephen Young

Colleges, School and Institutes

External organisations

  • King’s College London
  • Queen Mary, University of London
  • GlaxoSmithKline
  • Newcastle University
  • Janssen-Cilag Limited
  • Pfizer
  • University of Glasgow
  • University of Leeds
  • University College London Hospitals NHS Foundation Trust
  • UCB Pharma, Monheim
  • Elsai, UK.
  • AstraZeneca
  • AbbVie
  • Roche Prod
  • Protagen AG, UK.
  • MedImmune
  • University of Manchester
  • University of Oxford
  • University of Cambridge


Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.


Original languageEnglish
Pages (from-to)53-60
Number of pages8
JournalNature Reviews Rheumatology
Issue number1
Early online date7 Dec 2017
Publication statusE-pub ahead of print - 7 Dec 2017


  • Arthritis, Rheumatoid, Biomarkers, Biomedical Research, Cooperative Behavior, Genomics, History, 21st Century, Humans, Industry, Phenotype, Research, United Kingdom, Historical Article, Journal Article, Review